PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

BACKGROUND: Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such therapies has also been introduced into the treatment of other maligna...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagasaka, Misako, Zaki, Mark, Kim, Harold, Raza, S. Naweed, Yoo, George, Lin, Ho-sheng, Sukari, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109767/
https://www.ncbi.nlm.nih.gov/pubmed/27895920
http://dx.doi.org/10.1186/s40425-016-0187-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109767/
https://www.ncbi.nlm.nih.gov/pubmed/27895920
http://dx.doi.org/10.1186/s40425-016-0187-0

Ejemplares similares